{"id":"corticosteroids-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes (agitation, depression)"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Fluid retention"}]},"_chembl":{"chemblId":"CHEMBL3121562","moleculeType":"Small molecule","molecularWeight":"784.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Intravenous corticosteroids rapidly enter systemic circulation to exert broad immunosuppressive and anti-inflammatory effects. They inhibit phospholipase A2, reduce cytokine and chemokine synthesis, suppress T-cell proliferation, and stabilize lysosomal membranes. This makes them effective for acute inflammatory and autoimmune conditions requiring rapid systemic intervention.","oneSentence":"Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:52.978Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute inflammatory and autoimmune disorders"},{"name":"Severe allergic reactions"},{"name":"Cerebral edema"},{"name":"Acute exacerbations of chronic inflammatory conditions"},{"name":"Immunosuppression in transplantation"}]},"trialDetails":[{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT07270549","phase":"PHASE1, PHASE2","title":"Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome","status":"RECRUITING","sponsor":"CTNNB1 Foundation","startDate":"2025-11-01","conditions":"CTNNB1 Neurodevelopmental Syndrome","enrollment":12},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06780085","phase":"PHASE2","title":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":96},{"nctId":"NCT06936566","phase":"PHASE2","title":"MAGIC Ruxolitinib for aGVHD","status":"RECRUITING","sponsor":"John Levine","startDate":"2025-05-14","conditions":"Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects","enrollment":98},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05268289","phase":"PHASE2","title":"Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-10","conditions":"Lupus Nephritis","enrollment":240},{"nctId":"NCT06780098","phase":"PHASE2","title":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-28","conditions":"Lung Neoplasm","enrollment":144},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT06585774","phase":"PHASE3","title":"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-01-21","conditions":"Chronic Graft-versus-host-disease","enrollment":240},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT05848011","phase":"PHASE2","title":"A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MacroGenics","startDate":"2023-09-28","conditions":"Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent","enrollment":154},{"nctId":"NCT04127578","phase":"PHASE1, PHASE2","title":"Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2020-01-03","conditions":"Parkinson Disease","enrollment":32},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT07461961","phase":"PHASE2","title":"CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-07-01","conditions":"Cardiogenic Shock, Heart Failure, Inflammation","enrollment":30},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT06917937","phase":"NA","title":"The Additive Effect of Exercise in Addition to Corticosteroid Injection in Plantar Fasciitis","status":"COMPLETED","sponsor":"Kutahya Health Sciences University","startDate":"2018-09-16","conditions":"Plantar Fascitis","enrollment":40},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT05679401","phase":"PHASE3","title":"A Study With Imlifidase in Anti-GBM Disease","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2022-12-22","conditions":"Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome","enrollment":50},{"nctId":"NCT05789589","phase":"PHASE1, PHASE2","title":"Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2023-11-17","conditions":"Cancer, Metastasis, Metastatic Cancer","enrollment":46},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":850},{"nctId":"NCT06246513","phase":"PHASE3","title":"A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2024-01-15","conditions":"Limb-girdle Muscular Dystrophy","enrollment":17},{"nctId":"NCT02425904","phase":"PHASE2","title":"Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-05","conditions":"Langerhans Cell Histiocytosis","enrollment":25},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":100},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":"Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia","enrollment":36},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT00699751","phase":"PHASE3","title":"A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06-12","conditions":"Hormone Refractory Prostate Cancer, Bone Metastases","enrollment":921},{"nctId":"NCT07426484","phase":"PHASE4","title":"Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-07","conditions":"Cutaneous Squamous Cell Carcinoma, Skin Cancer","enrollment":80},{"nctId":"NCT07268248","phase":"NA","title":"1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study","status":"NOT_YET_RECRUITING","sponsor":"Paul Peng, MD PhD MSCR","startDate":"2026-06","conditions":"Allergic Reaction to Contrast Media, Hypersensitivity Reaction, Computed Tomography","enrollment":540},{"nctId":"NCT07281014","phase":"PHASE4","title":"Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-27","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT05345171","phase":"PHASE3","title":"Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2022-10-18","conditions":"OTC Deficiency","enrollment":32},{"nctId":"NCT00400946","phase":"PHASE3","title":"05-001: Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-04","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":800},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":128},{"nctId":"NCT07405151","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-11","conditions":"Oesophageal Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT06715709","phase":"PHASE4","title":"How Many Dexamethasone Doses Should Be Given Perioperatively?","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2025-03-25","conditions":"Arthropathy of Knee","enrollment":339},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"IgG4 Related Disease, IgG4-RD","enrollment":8},{"nctId":"NCT07387926","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-26","conditions":"Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT07258771","phase":"PHASE4","title":"Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2026-01-16","conditions":"Ulcerative Colitis Acute","enrollment":110},{"nctId":"NCT05917405","phase":"PHASE2","title":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-09-14","conditions":"Acute Myeloid Leukemia in Remission","enrollment":302},{"nctId":"NCT07378215","phase":"PHASE4","title":"The Effect of Corticosteroids on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study","status":"NOT_YET_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2026-02","conditions":"Postoperative Quality of Recovery, Health-Related Quality-of-Life, Quality of Life","enrollment":224},{"nctId":"NCT04305145","phase":"PHASE2","title":"Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-31","conditions":"Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III","enrollment":42},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT05220319","phase":"PHASE4","title":"CORTERAS STUDY: The Effect of Corticosteroids on Early Recovery After Major Surgery in Elderly Patients","status":"COMPLETED","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2022-02-16","conditions":"Inflammatory Response, Weakness, Muscle","enrollment":751},{"nctId":"NCT07362914","phase":"PHASE3","title":"Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-07","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT06781944","phase":"PHASE3","title":"OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-10-23","conditions":"Primary Membranous Nephropathy","enrollment":144},{"nctId":"NCT07345819","phase":"NA","title":"Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis","status":"NOT_YET_RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2026-04-01","conditions":"Orbital Cellulitis","enrollment":30},{"nctId":"NCT07353749","phase":"PHASE4","title":"Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms","status":"NOT_YET_RECRUITING","sponsor":"Duan Chuanzhi","startDate":"2026-01-30","conditions":"Unruptured Intracranial Aneurysms, Cerebrovascular Event, Hemorrhagic Stroke","enrollment":864},{"nctId":"NCT03875690","phase":"PHASE3","title":"Benefit of a Flash Dose of Corticosteroids in Digestive Surgical Oncology: a Randomized, Double Blind, Placebo-controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-07-02","conditions":"Elective Surgery for Any Digestive Cancer","enrollment":1200},{"nctId":"NCT06257706","phase":"PHASE4","title":"VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease","status":"RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2024-08-07","conditions":"Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn","enrollment":304},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT07340723","phase":"PHASE2","title":"Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-06-01","conditions":"GVHD,Acute, Stem Cell Transplant Complications","enrollment":168},{"nctId":"NCT07077850","phase":"NA","title":"Effect of IV Dexamethasone on Post-op Urinary Retention After Spinal Anesthesia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Quds University","startDate":"2025-08-20","conditions":"Post Operative Urinary Retention, Spinal Aneshtesia","enrollment":1084},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT07297914","phase":"PHASE2, PHASE3","title":"Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL","status":"NOT_YET_RECRUITING","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2026-01-15","conditions":"Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease","enrollment":1000},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT02001272","phase":"PHASE2","title":"EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-12","conditions":"Ovarian Cancer","enrollment":120},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT06126380","phase":"PHASE2","title":"Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Eledon Pharmaceuticals","startDate":"2023-10-25","conditions":"Kidney Transplant Rejection","enrollment":132},{"nctId":"NCT02377193","phase":"PHASE4","title":"Simulect Versus ATG in Sensitized Renal Transplant Patient","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-09","conditions":"Renal Transplant Rejection","enrollment":60},{"nctId":"NCT05643638","phase":"PHASE2","title":"A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD","status":"RECRUITING","sponsor":"Cynata Therapeutics Limited","startDate":"2024-03-04","conditions":"Graft Versus Host Disease, Acute","enrollment":60},{"nctId":"NCT04477629","phase":"PHASE2","title":"Belatacept in De Novo Heart Transplantation","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2020-08-06","conditions":"Heart Transplantation","enrollment":12},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT04817189","phase":"PHASE4","title":"Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2021-02-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":414},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT06120673","phase":"PHASE3","title":"REmission in Membranous Nephropathy International Trial (REMIT)","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2025-10-31","conditions":"Primary Membranous Nephropathy","enrollment":""},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT06462469","phase":"PHASE4","title":"Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-04","conditions":"Steroid-refractory Acute Graft Versus Host Disease","enrollment":36},{"nctId":"NCT04702256","phase":"PHASE3","title":"Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-09","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus (SLE)","enrollment":196},{"nctId":"NCT02473263","phase":"PHASE3","title":"Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-09","conditions":"Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit","enrollment":398},{"nctId":"NCT04744116","phase":"EARLY_PHASE1","title":"Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03721965","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-12-31","conditions":"Acute Graft-versus-host Disease","enrollment":2},{"nctId":"NCT04456439","phase":"","title":"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","status":"NO_LONGER_AVAILABLE","sponsor":"Mesoblast International Sàrl","startDate":"","conditions":"Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","enrollment":""},{"nctId":"NCT03401398","phase":"PHASE3","title":"Stress Hydrocortisone In Pediatric Septic Shock","status":"RECRUITING","sponsor":"Jerry Zimmerman","startDate":"2019-03-11","conditions":"Septic Shock","enrollment":500},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":473},{"nctId":"NCT06729593","phase":"PHASE3","title":"Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":87},{"nctId":"NCT06729606","phase":"PHASE3","title":"Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":471},{"nctId":"NCT04082533","phase":"PHASE4","title":"Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-24","conditions":"Pain, Arthrofibrosis, Osteoarthritis, Knee","enrollment":132},{"nctId":"NCT02444429","phase":"PHASE3","title":"3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-09-02","conditions":"Renal Transplantation","enrollment":346},{"nctId":"NCT05370976","phase":"PHASE2","title":"Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2022-09-13","conditions":"Cytomegalovirus Infections","enrollment":2},{"nctId":"NCT02630628","phase":"PHASE3","title":"Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-12-05","conditions":"Lupus Nephritis","enrollment":130},{"nctId":"NCT07072988","phase":"PHASE4","title":"Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-09-19","conditions":"Myasthenia Gravis, Generalized","enrollment":50},{"nctId":"NCT04762017","phase":"PHASE2","title":"OCS-05 in Patients With Optic Neuritis","status":"COMPLETED","sponsor":"Oculis","startDate":"2021-02-10","conditions":"Optic Neuritis","enrollment":36},{"nctId":"NCT04074187","phase":"PHASE2, PHASE3","title":"A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":21},{"nctId":"NCT07185633","phase":"PHASE2","title":"Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease","status":"NOT_YET_RECRUITING","sponsor":"Bin Gu","startDate":"2025-10-01","conditions":"aGVHD","enrollment":25},{"nctId":"NCT02114034","phase":"","title":"Cohort Analysis of Clinical and Biological Severe Childhood Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-11-12","conditions":"Severe Asthma","enrollment":362},{"nctId":"NCT04037605","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2020-02-09","conditions":"Sleep Restriction","enrollment":5},{"nctId":"NCT03142893","phase":"PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter y. Liu","startDate":"2017-05-08","conditions":"Sleep Restriction","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5697,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Solu-Medrol"],"phase":"marketed","status":"active","brandName":"Corticosteroids, IV","genericName":"Corticosteroids, IV","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute inflammatory and autoimmune disorders, Severe allergic reactions, Cerebral edema.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}